A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
Status:
Completed
Trial end date:
2016-03-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the single-dose pharmacokinetics of ASP2215 in
subjects with mild and moderate hepatic impairment to matched healthy subjects with normal
hepatic function.
This study will also assess the safety and tolerability of single-dose ASP2215 in subjects
with mild and moderate hepatic impairment and matched control subjects.